CCL20 and cystic fibrosis: Taken together, these data strongly implicated that increased CCL20/CCR6-driven ILC2 recruitment from the blood towards the inflamed lung tissue promotes the clinical exacerbation of CF (104), making it an attractive future research objective to experimentally investigate the therapeutic capacity of specific and already available pharmacological inhibitors of the CCL20-CCR6 axis, such as anti-CCR6 or anti-CCL20 antibodies or small molecular inhibitors (160), in this lung-affecting disease.